Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EPS (Weighted Average and Diluted) (2020 - 2025)

Spyre Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$77.78 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 9745.57% year-over-year to -$77.78; the TTM value through Dec 2025 reached -$102.37, down 291.02%, while the annual FY2025 figure was -$79.02, 2384.91% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$77.78 in Q4 2025 per SYRE's latest filing, down from -$0.15 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $40.14 in Q2 2023 to a low of -$77.78 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$5.57, with a median of -$0.49 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 14966.67% in 2023, then crashed 9745.57% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.69 in 2021, then soared by 2823.19% to $20.17 in 2022, then plummeted by 240.85% to -$28.41 in 2023, then surged by 97.22% to -$0.79 in 2024, then plummeted by 9745.57% to -$77.78 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's EPS (Weighted Average and Diluted) are -$77.78 (Q4 2025), -$0.15 (Q3 2025), and -$0.49 (Q2 2025).